SRRK Filings — Scholar Rock Holding Corp - FilingSpy
SRRK
Scholar Rock Holding Corp
A biopharmaceutical company in Cambridge, Massachusetts that develops antibody medicines for muscle-wasting diseases. Its lead therapy, apitegromab, targets a protein that limits muscle growth and is being tested for spinal muscular atrophy. Founded in 2012 by Harvard Medical School researchers, the company takes its name from Chinese "scholar's rocks"—eroded stones prized for sparking insight—because their rugged shapes resemble the protein structures it studies.
Apitegromab BLA resubmitted with a September 2026 PDUFA date as Scholar Rock's H1 net loss reaches $215.4M on pre-commercial spending.
The path to a first approved product now runs through September 30, 2026. remained zero and the net loss widened to $109.9 million for the quarter, as general and administrative expense rose 29% in the first half to support a commercial launch that hinges on the FDA's decision. The company holds $492.1 million in cash and marketable securities, enough to fund operations into the second half of 2027.
Key takeaways
The FDA accepted the resubmitted for apitegromab and set a new PDUFA action date of September 30, 2026, following the resolution of a third-party fill-finish facility issue that had triggered a in September 2025.
remained zero, as the company has no approved products and recognized its last collaboration revenue in early 2022.
The net loss widened to $109.9 million from $110.0 million in the same quarter a year ago, as a $49.7 million increase in general and administrative expense over the prior-year quarter was offset by a $3.4 million decline in research and development expense.
Section summaries
Management's Discussion and Analysis
Net loss widened to $215.4M in H1 2026 as G&A surged 29% for apitegromab launch prep, while R&D dipped slightly.
⌄
Total operating expenses rose 11.5% to $210.9M for H1 2026, driven by a $22.7M increase in G&A for commercial launch readiness.
R&D expenses decreased 0.9% to $110.0M in H1 2026 as lower apitegromab external costs from completed trials were offset by higher internal compensation.
General and administrative expense rose to $49.7 million, driven by the build-out of commercial infrastructure and headcount ahead of a potential apitegromab launch, while research and development expense dipped to $59.2 million as lower external costs from completed trials were partly offset by higher internal compensation.
Cash, cash equivalents, and marketable securities rose to $492.1 million at quarter-end, up from $367.6 million at year-end 2025, after the company raised $160.8 million in net proceeds from and drew $197.7 million in gross debt from a new Blue Owl .
The company used $103.7 million of the new debt proceeds to retire its prior Oxford/SVB loan, recording a $3.3 million in the first quarter.
What changed
The Phase 2 EMBRAZE trial of apitegromab in combination with GLP-1 receptor agonists for obesity, which earlier filings flagged for data in mid-2025, was not discussed this quarter; the company noted that apitegromab external costs fell partly due to the wind-down of the EMBRAZE trial.
The cash runway extended: management now projects the $492.1 million balance will fund operations into the second half of 2027, compared with the prior estimate of into 2027, after raising $160.8 million in equity and $197.7 million in debt during the first half.
The going-concern warning resolved in late 2024 remains absent, but the company stated it will need additional capital to complete clinical development and commercialization, a disclosure that echoes the pre-2024 financing risk flagged in earlier filings.
What to watch
FDA approval decision on the apitegromab BLA by the September 30, 2026 , and any update on the third-party facility's 'Official Action Indicated' status.
Top-line data from the Phase2 EMBRAZE trial of apitegromab in combination with GLP-1 receptor agonists for obesity, which was expected in mid-2025 but has not yet been reported.
The quarterly cash burn rate relative to the $492.1 million balance, particularly whether general and administrative spending is curtailed if the apitegromab launch faces further delays.
Initial data from the Phase1 trial of SRK-439, expected in the second half of 2026, which would validate the company's expansion into cardiometabolic disease.
Apitegromab external costs fell $4.0M in H1 2026 due to the wind-down of the Phase 3 SAPPHIRE and Phase 2 EMBRAZE trials, partially offset by new OPAL and FORGE trials.
Cash, equivalents, and marketable securities rose to $492.1M as of June 30, 2026, bolstered by $160.8M in ATM equity sales and $197.7M in new debt proceeds.
The company expects its current cash to fund operations into the second half of 2027 but will need additional capital to complete clinical development and commercialization.
The FDA accepted the resubmitted for apitegromab with a of September 30, 2026, following resolution of a third-party manufacturing facility issue.
From time to time, we are subject to various legal proceedings and claims that arise in the ordinary course of our business activities. Although the results of litigation and claims cannot be predicted with certainty, as of the date of this Quarterly Report, we do not believe we…
⌄
From time to time, we are subject to various legal proceedings and claims that arise in the ordinary course of our business activities. Although the results of litigation and claims cannot be predicted with certainty, as of the date of this Quarterly Report, we do not believe we are party to any claim or litigation the outcome of which, if determined adversely to us, would individually or in the aggregate be reasonably expected to have a material adverse effect on our business. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.
Apitegromab's FDA approval is delayed by a CRL due to third-party manufacturing issues, while the company builds commercial capabilities and faces financing risks.
⌄
The FDA issued a Complete Response Letter for apitegromab due to observations at a third-party fill-finish facility, delaying potential commercialization and risking a similar impact on the EMA review.
The company has never commercialized a product and is building sales, marketing, and medical affairs organizations for a potential launch in the U.S. and Europe, which may not be successful.
Unfavorable EU pricing and reimbursement decisions could significantly delay patient access and reduce , as negotiations are lengthy and subject to country-specific requirements.
The company relies on a limited number of third-party manufacturers, and a single-source supplier for drug substance and fill-finish, creating supply chain vulnerability.
The company has incurred significant net losses since inception, with an of $1.5 billion as of June 30, 2026, and will require additional capital to fund operations.
Changes or disruptions at the FDA, including funding cuts and personnel reductions, could prevent the timely review and potential approval of the resubmitted BLA.